Propranolol and breast cancer—a work in progress
Pantziarka, P., Bryan, B. A., Crispino, S., & Dickerson, E. B. (2018). Propranolol and breast cancer-a work in progress. Ecancermedicalscience, 12, ed82. doi:10.3332/ecancer.2018.ed82
The non-selective beta-blocker propranolol is a leading candidate for repurposing as a novel anti-cancer agent. Emerging evidence, including human data, suggests that there are multiple mechanisms of action particularly relevant to breast cancer. This editorial reviews a number of recent studies that show it has anti-metastatic activity that warrants clinical investigation, including investigation as a potential perioperative therapy in breast cancer.